Y-mAbs Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-21.43	-95.57	-55.28	-119.34	-81.03	-43.27	-19.16	-17.06
Depreciation & Amortization	0.74	0.84	0.78	0.4	0.17	0.03	0	0
Share-Based Compensation	14.45	25.6	19.33	16.14	4.66	1.97	0.61	0.26
Other Operating Activities	-20.99	-6.79	-67.4	11.58	2.71	0.05	2.68	5.63
Operating Cash Flow	-27.23	-75.92	-102.56	-91.23	-73.5	-41.23	-15.87	-11.17
Capital Expenditures	0	0	61.34	-0.18	-1.97	-0.23	0	0
Acquisitions	0	0	0	-2.61	0	0	0	0
Other Investing Activities	-	-	-0.3	-	-	-	-	-
Investing Cash Flow	0	0	61.04	-2.79	-1.97	-0.23	0	0
Share Issuance / Repurchase	0.1	0.08	108.31	2	134.7	99.77	89.84	18.97
Other Financing Activities	-	-	-	-	-	-1	-0.26	-
Financing Cash Flow	0.1	0.08	108.31	2	134.7	98.76	89.59	18.97
Exchange Rate Effect	0.01	0.04	0.13	-0.49	0.02	0.06	-0.1	0
Net Cash Flow	-27.13	-75.8	66.93	-92.5	59.27	57.36	73.61	7.81
Free Cash Flow	-27.23	-75.92	-41.21	-91.41	-75.46	-41.46	-15.87	-11.17
Free Cash Flow Margin	-32.11%	-116.32%	-118.10%	-440.51%	-	-	-	-
Free Cash Flow Per Share	-0.62	-1.74	-0.95	-2.28	-2.15	-1.44	-0.82	-0.79

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).